392 related articles for article (PubMed ID: 16802850)
1. A mechanistic approach for the scaling of clearance in children.
Edginton AN; Schmitt W; Voith B; Willmann S
Clin Pharmacokinet; 2006; 45(7):683-704. PubMed ID: 16802850
[TBL] [Abstract][Full Text] [Related]
2. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
Björkman S
Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
[TBL] [Abstract][Full Text] [Related]
3. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
[TBL] [Abstract][Full Text] [Related]
4. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
Alcorn J; McNamara PJ
Clin Pharmacokinet; 2002; 41(13):1077-94. PubMed ID: 12403644
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
Edginton AN; Schmitt W; Willmann S
Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
[TBL] [Abstract][Full Text] [Related]
6. Optimizing pediatric dosing: a developmental pharmacologic approach.
Anderson GD; Lynn AM
Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
[TBL] [Abstract][Full Text] [Related]
7. Impact of obesity on drug metabolism and elimination in adults and children.
Brill MJ; Diepstraten J; van Rongen A; van Kralingen S; van den Anker JN; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):277-304. PubMed ID: 22448619
[TBL] [Abstract][Full Text] [Related]
8. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.
Anderson GD
Clin Pharmacokinet; 2005; 44(10):989-1008. PubMed ID: 16176115
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Clearance in Neonates and Infants (≤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
Mahmood I; Ahmad T; Mansoor N; Sharib SM
J Clin Pharmacol; 2017 Apr; 57(4):476-483. PubMed ID: 27704554
[TBL] [Abstract][Full Text] [Related]
10. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
Miners JO; Knights KM; Houston JB; Mackenzie PI
Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060
[TBL] [Abstract][Full Text] [Related]
11. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.
Kilford PJ; Stringer R; Sohal B; Houston JB; Galetin A
Drug Metab Dispos; 2009 Jan; 37(1):82-9. PubMed ID: 18832476
[TBL] [Abstract][Full Text] [Related]
12. Predicting the "First dose in children" of CYP3A-metabolized drugs: Evaluation of scaling approaches and insights into the CYP3A7-CYP3A4 switch at young ages.
Strougo A; Yassen A; Monnereau C; Danhof M; Freijer J
J Clin Pharmacol; 2014 Sep; 54(9):1006-15. PubMed ID: 24676942
[TBL] [Abstract][Full Text] [Related]
13. Developmental pharmacokinetics.
Anderson GD
Semin Pediatr Neurol; 2010 Dec; 17(4):208-13. PubMed ID: 21183126
[TBL] [Abstract][Full Text] [Related]
14. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Cubitt HE; Houston JB; Galetin A
Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
[TBL] [Abstract][Full Text] [Related]
15. Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.
Sayama H; Takubo H; Komura H; Kogayu M; Iwaki M
AAPS J; 2014 Sep; 16(5):1018-28. PubMed ID: 24912798
[TBL] [Abstract][Full Text] [Related]
16. Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.
Alcorn J; McNamara PJ
Clin Pharmacokinet; 2002; 41(12):959-98. PubMed ID: 12222995
[TBL] [Abstract][Full Text] [Related]
17. How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach.
Johnson TN; Jamei M; Rowland-Yeo K
Drug Metab Dispos; 2016 Jul; 44(7):1090-8. PubMed ID: 26862026
[TBL] [Abstract][Full Text] [Related]
18. Prediction of drug clearance in children.
Foissac F; Bouazza N; Valade E; De Sousa Mendes M; Fauchet F; Benaboud S; Hirt D; Tréluyer JM; Urien S
J Clin Pharmacol; 2015 Jul; 55(7):739-47. PubMed ID: 25721251
[TBL] [Abstract][Full Text] [Related]
19. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches.
Miners JO; Smith PA; Sorich MJ; McKinnon RA; Mackenzie PI
Annu Rev Pharmacol Toxicol; 2004; 44():1-25. PubMed ID: 14744236
[TBL] [Abstract][Full Text] [Related]
20. Principles and clinical application of assessing alterations in renal elimination pathways.
Tett SE; Kirkpatrick CM; Gross AS; McLachlan AJ
Clin Pharmacokinet; 2003; 42(14):1193-211. PubMed ID: 14606929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
